Found: 39
Select item for more details and to access through your institution.
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2024, v. 20, n. 8, p. 5143, doi. 10.1002/alz.13859
- By:
- Publication type:
- Article
Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2024, v. 20, n. 3, p. 1839, doi. 10.1002/alz.13532
- By:
- Publication type:
- Article
Human CSF pharmacoproteomics establishes in vivo‐relevant BACE1 substrates as pharmacodynamic biomarkers for chronic BACE inhibition in clinical trials.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.082943
- By:
- Publication type:
- Article
Current understanding of AD pathophysiology and impact of amyloid beta–targeted treatments on biomarkers and clinical endpoints.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 8, p. 1586, doi. 10.1002/alz.12769
- By:
- Publication type:
- Article
API generation program: Active immunotherapy CAD106 slows amyloid deposition in cognitively unimpaired APOE4 homozygotes.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.051287
- By:
- Publication type:
- Article
The API Generation program: Biomarker phenotyping of cognitively unimpaired participants screened in Generation study 1 and Generation study 2: Alzheimer's Prevention Initiative (API) Generation program: Baseline characteristics and umibecestat results during treatment and follow‐up
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.041143
- By:
- Publication type:
- Article
The API Generation program: Umibecestat treatment and discontinuation effects on hippocampal and whole brain volumes in the overall population and amyloid‐negative APOE4 homozygotes: Alzheimer's Prevention Initiative (API) Generation program: Baseline characteristics and umibecestat results during treatment and follow‐up
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.041142
- By:
- Publication type:
- Article
Umibecestat in the API Generation program: Worsening in RBANS and/or CDR on treatment reverses after wash‐out: Alzheimer's Prevention Initiative (API) Generation program: Baseline characteristics and umibecestat results during treatment and follow‐up
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.041140
- By:
- Publication type:
- Article
The Generation program: Baseline characteristics of cognitively unimpaired APOE4 carriers recruited for Generation study 1 and Generation study 2: Alzheimer's Prevention Initiative (API) Generation program: Baseline characteristics and umibecestat results during treatment and follow‐up
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.041139
- By:
- Publication type:
- Article
The Alzheimer's prevention initiative Generation program: A global perspective on best practices for site support and engagement to accelerate participant recruitment: Clinical trial design and implementation.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.039186
- By:
- Publication type:
- Article
P3‐010: THE LARGEST GLOBAL SURVEY TO DATE OF ADULT PERCEPTIONS OF ALZHEIMER'S DISEASE AND CLINICAL TRIAL PARTICIPATION.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P928, doi. 10.1016/j.jalz.2019.06.3036
- By:
- Publication type:
- Article
FTS3‐01‐01: UMIBECESTAT (CNP520) IS NOT ASSOCIATED WITH CHANGES IN HIPPOCAMPAL MORPHOLOGY IN RATS OR CHANGES IN CSF AD BIOMARKERS IN HUMANS TREATED FOR 3 MONTHS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P872, doi. 10.1016/j.jalz.2019.06.4618
- By:
- Publication type:
- Article
F2‐03‐04: ASSESSING CLINICAL MEANINGFULNESS OF OUTCOMES IN THE ALZHEIMER'S PREVENTION INITIATIVE GENERATION PROGRAM.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P520, doi. 10.1016/j.jalz.2019.06.4427
- By:
- Publication type:
- Article
P4‐339: THE MEDIA STUDY: A NOVEL METHOD FOR EVALUATING DIGITAL ENDPOINTS IN ALZHEIMER'S DISEASE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P1596, doi. 10.1016/j.jalz.2018.07.162
- By:
- Publication type:
- Article
P2‐036: WHY AND HOW WE THINK THAT CLINICAL TRIALS OF THERAPIES FOR ALZHEIMER'S DISEASE CAN BE SUCCESSFUL: A SIMULATION PLATFORM FOR PRECLINICAL AD.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P680, doi. 10.1016/j.jalz.2018.06.720
- By:
- Publication type:
- Article
P1‐607: INSIGHTS TO MODEL ALZHEIMER'S PROGRESSION IN REAL LIFE (IMAP): RATIONALE, OBJECTIVE, AND METHODOLOGY.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P572, doi. 10.1016/j.jalz.2018.06.620
- By:
- Publication type:
- Article
P1‐071: ESTIMANDS IN PRECLINICAL AD: CASE STUDY IN THE GENERATION PROGRAM.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P298, doi. 10.1016/j.jalz.2018.06.073
- By:
- Publication type:
- Article
The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's disease.
- Published in:
- Alzheimer's Research & Therapy, 2020, v. 12, n. 1, p. 1, doi. 10.1186/s13195-020-00633-2
- By:
- Publication type:
- Article
RESULTS FROM A 3-MONTH STUDY IN HEALTHY SUBJECTS AGED 60 YEARS WITH THE BACE INHIBITOR CNP520.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P256, doi. 10.1016/j.jalz.2017.06.118
- By:
- Publication type:
- Article
RATIONALE FOR SELECTION OF PRIMARY ENDPOINTS IN THE ALZHEIMER PREVENTION INITIATIVE GENERATION STUDY IN COGNITIVELY HEALTHY APOE4 HOMOZYGOTES.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P1452, doi. 10.1016/j.jalz.2017.07.507
- By:
- Publication type:
- Article
RATIONALE FOR CNP520 DOSE SELECTION FOR THE PIVOTAL CLINICAL PROGRAM IN PRECLINICAL AD.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P601, doi. 10.1016/j.jalz.2017.07.245
- By:
- Publication type:
- Article
RESULTS FROM A FIRST-IN-HUMAN STUDY WITH THE BACE INHIBITOR CNP520.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P200, doi. 10.1016/j.jalz.2016.06.351
- By:
- Publication type:
- Article
Long-term administration of active immunotherapy CAD106 in phase IIa open-label extension studies in Alzheimer's disease patients
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Safety and tolerability of active immunotherapy cad106 in two phase ii studies in Alzheimer's patients
- Published in:
- 2011
- By:
- Publication type:
- Abstract
A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease
- Published in:
- 2011
- By:
- Publication type:
- Abstract
Longitudinal ADC changes in Alzheimer's disease in a multi-center clinical trial setting
- Published in:
- 2011
- By:
- Publication type:
- Abstract
Longitudinal ADC changes in Alzheimer's disease in a multicenter clinical trial setting
- Published in:
- 2011
- By:
- Publication type:
- Abstract
Aβ-specific antibodies induced by active immunotherapy CAD106 engage Aβ in plasma in AD patients
- Published in:
- 2011
- By:
- Publication type:
- Abstract
The active Aβ immunotherapy CAD106 increases plasma Aβ in monkeys
- Published in:
- 2010
- By:
- Publication type:
- Abstract
Optimization of the treatment regimen with active Aß immunotherapy CAD106 in alzheimer patients
- Published in:
- 2010
- By:
- Publication type:
- Abstract
Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease.
- Published in:
- Alzheimer's Research & Therapy, 2015, v. 7, n. 1, p. 1, doi. 10.1186/s13195-015-0108-3
- By:
- Publication type:
- Article
Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2023, v. 9, n. 4, p. 1, doi. 10.1002/trc2.12434
- By:
- Publication type:
- Article
Current understanding of AD pathophysiology and impact of amyloid-beta targeted treatments on biomarkers and clinical endpoints.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2022, v. 8, n. 1, p. 1, doi. 10.1002/trc2.12361
- By:
- Publication type:
- Article
The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2019, v. 5, n. 1, p. 216, doi. 10.1016/j.trci.2019.02.005
- By:
- Publication type:
- Article
Measuring cognition and function in the preclinical stage of Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2018, v. 4, n. 1, p. 64, doi. 10.1016/j.trci.2018.01.003
- By:
- Publication type:
- Article
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease.
- Published in:
- Dementia & Geriatric Cognitive Disorders Extra, 2011, v. 1, n. 1, p. 163, doi. 10.1159/000328929
- By:
- Publication type:
- Article
Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer's disease.
- Published in:
- Alzheimer's Research & Therapy, 2023, v. 15, n. 1, p. 1, doi. 10.1186/s13195-023-01183-z
- By:
- Publication type:
- Article
Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: Two randomized phase 2 studies.
- Published in:
- 2016
- By:
- Publication type:
- journal article
AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
- Published in:
- Movement Disorders, 2013, v. 28, n. 13, p. 1838, doi. 10.1002/mds.25561
- By:
- Publication type:
- Article